inflammasome Inhibitors
3 drugsAbout inflammasome
The inflammasome is a multi-protein complex in the innate immune system. It activates inflammatory responses by processing pro-inflammatory cytokines like IL-1β and IL-18, triggering pyroptosis.
The inflammasome is a therapeutic target due to its role in inflammation. Currently, there is no genetic evidence directly linking the inflammasome to specific diseases.
Three FDA-approved drugs target the inflammasome: COLCRYS, GLOPERBA, and MITIGARE. All three drugs are small molecules, addressing various therapeutic areas.
Top inflammasome Drugs
The competitive landscape includes three companies with approved drugs: AR HOLDING CO INC, SCILEX PHARMS, and Hikma.
The limited number of players suggests a relatively unconcentrated market with potential entry opportunities.
inflammasome Drug Modality Landscape
Modalities
Routes of Administration
inflammasome is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
inflammasome Clinical Trials 206 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on inflammasome. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 26 | 24 | 1 | 1 | 96% |
| Phase 2 | 73 | 40 | 11 | 22 | 78% |
| Phase 3 | 59 | 22 | 7 | 30 | 76% |
| Phase 4 | 48 | 26 | 5 | 16 | 84% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
inflammasome Drug Approval Timeline (2014 - 2019)
The first drug targeting the inflammasome was approved in 2009 (COLCRYS), with the most recent approval in 2019 (GLOPERBA).
The approval timeline indicates a slow but steady interest in targeting this pathway, suggesting room for innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 3 companies competing
- • Market share by company
Full Drug Portfolio
- • All 3 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 3-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 140 (15 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on inflammasome. A trial counts if an approved drug acting on inflammasome is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.